Pharma Sector Gains Momentum as Johnson & Johnson Shows Potential Breakout

Pharmaceutical stocks have recently diverged from the broader market, emerging as a key source of leadership within healthcare. Eli Lilly, a bellwether in the industry, has already surged to all‑time highs, boosting sector proxies such as the iShares U.S. Pharmaceuticals ETF (IHE). This positive momentum is creating a favorable environment for other large names, notably Johnson & Johnson (JNJ).

IHE continues its cyclical uptrend toward new highs, confirmed by a weekly MACD crossover that signals renewed intermediate‑term momentum. While Lilly accounts for roughly 25 % of IHE, the ETF’s strength suggests broader leadership beyond a single stock. The IHE/SPX ratio is rebounding off support at its 200‑day moving average, indicating that pharma is positioned for further outperformance in the coming weeks. The long‑term outlook remains solid, underscored by the rising slope of the 40‑week moving average.

Johnson & Johnson is also improving. Technical indicators point to a possible reassertion of leadership after a consolidation phase. Weekly stochastics have turned oversold, a pattern that often aligns with intermediate‑term lows, and the weekly MACD histogram shows consecutive upticks. Key support lies near the rising 200‑day moving average (~$213), while resistance clusters around $249.

On the daily chart, JNJ displays a counter‑trend “buy” signal from the DeMARK Indicators® and a bullish MACD crossover, reinforcing the likelihood of near‑term upside. The stock has broken back above its 50‑day moving average and entered the daily cloud, making the momentum shift more apparent.

Relative strength further favors JNJ. The JNJ/SPX ratio has staged a counter‑trend cyclical ascent since early 2025, forming higher lows within a multi‑year downtrend. Although the broader trend remains bearish, the cyclical move appears durable. With the ratio approaching support at its 40‑week moving average, JNJ is at a relative proving ground and may advance higher in both absolute and relative terms.

Overall, pharma leadership is reinforced by IHE’s push to new highs and a fresh weekly MACD crossover, while Johnson & Johnson exhibits intermediate‑term signals that could precede a rotation into other large‑cap leaders. With support at the 200‑day moving average and resistance near $249, the risk‑reward profile for JNJ is becoming clearer as momentum turns upward.

Source link